FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
SELLAS Life Sciences Group, Inc. Stock AnalysisComprehensive stock analysis for SELLAS Life Sciences Group, Inc. (SLS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSLS
SLS
SELLAS Life Sciences Group, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SLS
Home🔹Stocks🔹SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc.

SLS•NASDAQ

SELLAS Life Sciences Group, Inc.

SLS•NASDAQ
Market cap
$1.88B
Sentiment

Your view on SLS

Mkt Cap
$1.88B
Sentiment
Your view
SLS
SELLAS Life Sciences Group, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SLS
Company Overview

Overview

What the company does, where it operates, and who runs it.

About SELLAS Life Sciences Group, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Angelos M. Stergiou ScD h.c.
Headquarters
Times Square Tower, New York City, NY, US
Industry
Biotechnology
Sector
Healthcare
CEO
Angelos M. Stergiou ScD h.c.
Headquarters
Times Square Tower, New York City, NY, US
Description

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News